Abstract: Provided are small molecule inhibitors of ubiquitin specific protease 1 (USP1) activity and methods for their use in treating and characterizing cancers. The small molecule USP1 inhibitors of the invention are particularly useful in the treatment of cancers that are resistant to DNA cross-linking agents.

Abstract: Reserves of immortalized genetic material are stored in a bank for unlimited genetic analysis, tissue creation, lab-in-a-dish, and the like. The bank serves as a valuable platform for a variety of applications, including biological applications (e.g., genotyping, drug screening, personalized medicine), that require repeated testing, access to a biological sample, and maintenance over a long period of time. For example, a biological sample is stored as induced pluripotent stem cells (iPSCs) that can be used to generate an unlimited supply of genetic material when needed by a user. In this way, for instance, the generation of excess genetic material from additional samples provided by an individual can be avoided and costs to an organization associated with producing genetic material from biological sample can be deferred until necessary.

Abstract: Described herein is a managed, indexed repository of hematopoietic stem cell (HSC) lines and/or blood progenitor cell lines derived from induced pluripotent stem cells (iPSCs) (or embryoid bodies formed from iPSCs), wherein each of the HSC lines, blood progenitor cell lines, embryoid bodies, and/or iPSC lines has corresponding data comprising a set of characterized HLA loci, said corresponding data being stored in a searchable database for retrieval of one or more matching physical cell lines upon query. The repository comprises an HLA-indexed bank of iPSCs, embryoid bodies, HSCs, and/or blood progenitor cells for each of a set of HLA types, for identification and provision of allogeneic cell lines suitable for transplantation to reestablish hematopoietic function in patients with damaged, diseased, or otherwise abnormal bone marrow and/or immune system.

Abstract: Presented herein are systems and methods related to a scalable and platform-agnostic framework that facilitates the creation of personal genetic profile products. In particular, in certain embodiments, the systems and methods described herein facilitate the creation, storage, organization, and maintenance (e.g. updating) of data corresponding to the relationships between particular variations that may occur in an individual's DNA (e.g. variants of different specific SNPs) and the health-related phenotypes that they influence. The data stored in this manner can be used as a template not only for presenting personal genetic profile assessments to an individual in an informative and user-friendly manner, but also for the rapid, automated creation of personal genetic profile assessments of a plurality of individuals from data corresponding to genotyping measurements of biological samples provided by the individuals.

Abstract: Reserves of immortalized genetic material are stored in a bank for providing a resource (e.g., artificial gametes) for couples (e.g., same sex couples) to produce biologically-related children. The reserves provide the ability to derive sperm from induced pluripotent stem cells (iPSCs) of one partner and/or eggs from iPSCs of the other partner. For example, a biological sample is stored as iPSCs that can be used to generate an unlimited supply of genetic material (e.g., artificial gametes for conception) when needed by a user (e.g., a year or more after the sample is provided, e.g., 5 years or more after the sample is provided). Such a bank is helpful for an individual in a same sex (or infertile) couple who desires to have biological children at some point during his/her lifetime, but does not plan to have children in the immediate timeframe, for example.

Abstract: Described herein are various systems and methods for customizing cell culture media for optimized cell proliferation based on genetic traits of the cells. Factors of the cells, such as genetics, can determine the optimum cell culture conditions for growth and use of individual cells in vitro. In certain embodiments, genetics can determine sensitivity from a toxic perspective. In certain embodiments, genetics can determine what concentration(s) of growth factor(s) and nutrient(s) are required for optimum growth.

Abstract: The present invention relates to 2-amino-4-arylpyrimidine and 2-amino-4-aryltriazine compounds as inhibitors of heat shock protein 90 family of chaperone proteins. The invention also features pharmaceutical compositions and kits that include the compounds and compositions of the invention. The invention further relates to the medical use of these compounds and compositions for the treatment of a disorder in a subject. For example, the disorder is a neurodegenerative disease.

Abstract: Described herein are various systems, methods, and apparatus for systematic creation of isolated homogeneous colonies of cells from vector-based lineages. The vector-based lineages may originate from multiple types of viral vector families (e.g., Paramyx-oviridae, Retroviridae, Parvoviridae) or non-natural engineered vectors or a plurality of vector combinations, for example. In certain embodiments, the isolated homogeneous colonies of cells are vector-free sub-colonies; in other embodiments, the isolated homogeneous colonies of cells are homogeneous vector sub-colonies. In other embodiments, vector mixed sub-colonies are created. The disclosed systems, methods, and apparatus are useful for inducible pluripotent stem cell (iPSC) production and work by selectively binding to one or more corresponding protein markers expressed on the surface of a cell that indicate that cellular reprogramming has occurred. Software is used to automate the purification and isolation of the iPSCs produced.

Abstract: Presented herein are methods and systems for using genotyping data of an individual to create and/or modify in-game avatars. Genotyping data is used to create and update avatar objects. Avatar objects are data structures that comprise data, based on genotyping data, that define individual avatars and can be exported for import into a game to generate an avatar. Traits of an individual are characterized by feature values included in an avatar object. Avatars generated from avatar objects may appear to physically resemble an individual or may have an appearance that fits the thematic elements of a game while still reflecting the phenotype of the individual (based on the individual's genotyping data). Avatars may be used in games for entertainment, for interactive or realistic health tracking, simulations, simulated work environments, or other similar purposes.

Abstract: This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g., a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation.

Abstract: The present invention relates to 2-amino-4-arylpyrimidine and 2-amino-4-aryltriazine compounds as inhibitors of heat shock protein 90 family of chaperone proteins. The invention also features pharmaceutical compositions and kits that include the compounds and compositions of the invention. The invention further relates to the medical use of these compounds and compositions for the treatment of a disorder in a subject. For example, the disorder is a neurodegenerative disease.

Abstract: Described herein are systems and methods to record and track, via a graphical user interface, biological samples, and biological material extracted therefrom, used to generate genotyping data. As biological samples are processed in several stages to extract biological material and perform genotyping tests, IDs are assigned to biological samples and biological material for individuals as well as well plates used during processing of the biological samples and the biological material in order to organize the samples and the tests. Biological samples are assigned to well plates for use in extracting biological material. Biological material is assigned to genotyping plates for use in performing genotyping tests. By associating IDs corresponding to biological samples or biological material with IDs for well plates or genotyping plates, respectively, a user can track which extractions and/or tests need to be performed and record which biological samples have been received or genotyping plates analyzed.

Abstract: Disclosed are methods for diagnosing Parkinson's disease, or identifying a risk of developing Parkinson's disease, comprising measuring the amount of a biomolecule in a blood sample, liver sample, or hepatocyte. Also disclosed are methods for preventing or treating Parkinson's disease, comprising administering a therapeutically effective plurality of hepatocytes to a subject in need thereof.

Abstract: The techniques described herein provide for improved efficiency of iPSC production from biological cells. The approach achieves improved iPSC production efficiency by obtaining a set of cells whose cell cycles are synchronized at a specific, desired cell cycle phase, such as mitotic phase (also referred to as M phase). The efficacy with which such synchronized cells can be transformed into iPSCs is higher than for an arbitrary set of cells that comprises cells at a variety of different stages in their cycles. Accordingly, the approaches described herein allow efficient generation of iPSCs, thereby facilitating myriad technologies for personalized and regenerative medicine that rely upon the effective production of iPSCs.

Abstract: Presented herein are systems and methods for automatically identifying and recommending purchases (e.g., in-app purchases) to a user based on the user's personal genetic profile. In certain embodiments, offers for such purchases are conveniently presented in the same software application (e.g., smartphone app or other computing device application) in which a user securely accesses his or her personalized genetic profile test results. Also presented herein are systems and methods for computer application developers to customize apps for presentation of recommended purchases based on a user's personal genetic profile. In certain embodiments, the systems and methods described herein provide for issuing of genetically tailored notifications to one or more mobile health devices of an individual based on an assessment of the individual's genetic profile. Such notifications, for example, can assist an individual in their adherence to particular recommended regiments, such as workout regimens.

Abstract: Presented herein are systems and methods related to a scalable and platform-agnostic framework that facilitates the creation of personal genetic profile products. In particular, in certain embodiments, the systems and methods described herein facilitate the creation, storage, organization, and maintenance (e.g. updating) of data corresponding to the relationships between particular variations that may occur in an individual's DNA (e.g. variants of different specific SNPs) and the health-related phenotypes that they influence. The data stored in this manner can be used as a template not only for presenting personal genetic profile assessments to an individual in an informative and user-friendly manner, but also for the rapid, automated creation of personal genetic profile assessments of a plurality of individuals from data corresponding to genotyping measurements of biological samples provided by the individuals.

Abstract: Provided are small molecule inhibitors of ubiquitin specific protease 1 (USP1) activity and methods for their use in treating and characterizing cancers. The small molecule USP1 inhibitors of the invention are particularly useful in the treatment of cancers that are resistant to DNA cross-linking agents.

Abstract: The present invention relates to 2-amino-4-arylpyrimidine and 2-amino-4-aryltriazine compounds as inhibitors of heat shock protein 90 family of chaperone proteins. The invention also features pharmaceutical compositions and kits that include the compounds and compositions of the invention. The invention further relates to the medical use of these compounds and compositions for the treatment of a disorder in a subject. For example, the disorder is a neurodegenerative disease.

Abstract: This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g., a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation.

Abstract: Herein, compounds and compositions for use in treating diseases relating to inclusion formation and stress granules are described. Methods for screening for modulation of TDP-43 aggregation are also described.